Goldenwell Biotech restates June 2025-quarter results, posts USD 68,836 six-month net loss

GOLDENWELL BIOTECH INC

GOLDENWELL BIOTECH INC

GWLL

0.00
  • Goldenwell Biotech restated its quarterly financial statements for the quarter ended June 30, 2025 in a Form 10-Q/A filed June 26, 2026.
  • Restatement reversed USD 37,500 of service revenue previously recorded for April 1, 2025 to June 30, 2025.
  • Net loss for the three months ended June 30, 2025 widened to USD 30,300 from USD 5,220 previously reported.
  • Total assets at June 30, 2025 rose to USD 267,315 from USD 251,295, reflecting USD 16,020 classified as prepaid OTCQB fee.
  • Unearned service revenue at June 30, 2025 increased to USD 100,000 from USD 62,500; accrued legal fees were recorded at USD 7,760.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Goldenwell Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004054), on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.